PPIDT00304
Drug Information
| Name | Durvalumab |
|---|---|
| Sequence | EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB11714 |
| Type | biotech |
| Indication | Durvalumab is indicated for the treatment of adults with the following conditions: **Non-small cell lung cancer (NSCLC)** - unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.[L44121] - metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations, in combination with [tremelimumab] and platinum-based chemotherapy.[L44121, L46188] - in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by durvalumab continued as a single agent as adjuvant treatment after surgery, is indicated for the treatment of adult patients with resectable (tumours ≥ 4 cm and/or node-positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.[L51209] **Small cell lung cancer (SCLC)** - extensive-stage SCLC in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line therapy.[L12624] - limited-stage SCLC in adults whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.[L51928] **Biliary tract cancer** - locally advanced or metastatic biliary tract cancer (BTC) in combination with [gemcitabine] and cisplatin.[L43055] **Hepatocellular carcinoma** - unresectable hepatocellular carcinoma (uHCC) alone or in combination with [tremelimumab].[L12627, L43647, L46188] **Endometrial cancer** - in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This is followed by maintenance treatment with either durvalumab as monotherapy or in combination with [olaparib] in endometrial cancer that is mismatch repair deficient (dMMR).[L12627] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Intravenous |
120 mg/2.4mL
|
| Injection, solution | Intravenous |
500 mg/10mL
|
| Injection, solution, concentrate | Intravenous |
120 mg/2.4ml
|
| Injection, solution, concentrate | Intravenous |
50 mg/ml
|
| Injection, solution, concentrate | Intravenous |
50 mg/1ml
|
| Injection, solution, concentrate | Intravenous; Parenteral |
50 MG/ML
|
| Solution | Intravenous |
50 mg / mL
|
| Injection, solution, concentrate | — |
120 mg/2.4ml
|
| Injection, solution, concentrate | — |
500 mg/10ml
|
| Solution | Intravenous |
50 mg/ml
|
| Injection, solution | Intravenous |
50 MG/ML
|
| Solution, concentrate | Intravenous |
5000000 mg
|
| Solution | Intravenous |
500.000 mg
|